Mixed DyslipidemiaPhase 1NCT07319559
Clinical Trial to Evaluate the Safety, Pharmacokinetic Characteristics of DW5124 and DW5124-R, and the Effect of Food on DW5124 in Healthy Adult Volunteers
A Phase 1 study testing DW5124 and DW5124-R in people with Mixed Dyslipidemia, run by Daewon Pharmaceutical Co., Ltd. at 1 site in South Korea.
Trial summary
This study aimed to evaluate the safety and pharmacokinetic characteristics of DW5124 and DW5124-R, and the effect of food on DW5124, in healthy adult volunteers. Read more about this study
- Who is it for?
- Ages 19 to 65 yearsHealthy volunteers can take part
- Conditions the study is for
- Mixed Dyslipidemia
- What is being tested?
- DW5124 and DW5124-R
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 55 participants
- Where
- 1 siteSouth Korea
- Study dates
- 8 May 2025to 5 Jun 2025
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 19 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Healthy Volunteers who are ≥19 years and >65 years old
- Body weight ≥50.0 kg and BMI between 18.0 and 30.0 kg/m2
Who cannot join
- Clinically significant Medical History
- In the case of women, pregnant(Urine-HCG positive) or lactating women
Trial locations and contacts
1 site in 1 country.
About this study
This study aimed to evaluate the safety and pharmacokinetic characteristics of DW5124 and DW5124-R, and the effect of food on DW5124, in healthy adult volunteers.
- Conditions
- Mixed Dyslipidemia
- Being tested
- DW5124, DW5124-R
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
DW5124Drug
DW5124 on fasted or fed condition
DW5124-RDrug
DW5124-R on fasted or fed condition
| Study group | Role | What they receive |
|---|---|---|
| Sequence A | Experimental | cross-over Receives: Drug: DW5124; Drug: DW5124-R |
| Sequence B | Experimental | cross-over Receives: Drug: DW5124; Drug: DW5124-R |
| Sequence C | Experimental | cross-over Receives: Drug: DW5124; Drug: DW5124-R |
| Sequence D | Experimental | cross-over Receives: Drug: DW5124; Drug: DW5124-R |
| Sequence E | Experimental | cross-over Receives: Drug: DW5124; Drug: DW5124-R |
| Sequence F | Experimental | cross-over Receives: Drug: DW5124; Drug: DW5124-R |
What is being measured
The primary outcome is the main question the study is designed to answer.
Peak Plasma Concentration (Cmax)
Pharmacokinetics of DW5124-fed and DW5124-fasting, Pharmacokinetics of DW5124-fed and DW5124-R-fed
Measured: up to 72 hour
Area under the plasma concentration versus time curve (AUC)
Pharmacokinetics of DW5124-fed and DW5124-fasting, Pharmacokinetics of DW5124-fed and DW5124-R-fed
Measured: up to 72 hour
Secondary outcomes (4)
Time to maximum plasma concentration (Tmax)
Pharmacokinetics of DW5124-fed, DW5124-fasting, DW5124-R-fed
Measured: up to 72 hour
Terminal half life (t1/2)
Pharmacokinetics of DW5124-fed, DW5124-fasting, DW5124-R-fed
Measured: up to 72 hour
Apparent clearance (CL/F)
Pharmacokinetics of DW5124-fed, DW5124-fasting, DW5124-R-fed
Measured: up to 72 hour
Apparent volume of distribution (Vd/F)
Pharmacokinetics of DW5124-fed, DW5124-fasting, DW5124-R-fed
Measured: up to 72 hour
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Jan 2026
- Study start8 May 2025
- Primary completion11 May 2025
- Study completion5 Jun 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Mixed DyslipidemiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Enrolment
- 55 participants (actual)
Sponsor and investigators
- Lead sponsor
- Daewon Pharmaceutical Co., Ltd.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07319559
- Sponsor's protocol ID
- DW5124-101
- Status last verified
- Dec 2025
- First submitted
- 22 Dec 2025
- Last updated
- 6 Jan 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 6 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Clinical Trial to Evaluate the Safety, Pharmacokinetic Characteristics of DW5124 and DW5124-R, and the Effect of Food on DW5124 in Healthy Adult Volunteers
- ClinicalTrials.gov ID
- NCT07319559
- Acronym / sponsor ID
- DW5124-101
- Conditions
- Mixed Dyslipidemia
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 55 participants (actual)
- Lead sponsor
- Daewon Pharmaceutical Co., Ltd.Industry (pharma, biotech, devices)
- Study start
- 8 May 2025 (actual)
- Primary completion
- 11 May 2025 (actual)
- Study completion
- 5 Jun 2025 (actual)
- First posted
- 6 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aimed to evaluate the safety and pharmacokinetic characteristics of DW5124 and DW5124-R, and the effect of food on DW5124, in healthy adult volunteers.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Number of arms
- 6
| Arm | Type | Receives |
|---|---|---|
| Sequence A | Experimental | Drug: DW5124, Drug: DW5124-Rcross-over |
| Sequence B | Experimental | Drug: DW5124, Drug: DW5124-Rcross-over |
| Sequence C | Experimental | Drug: DW5124, Drug: DW5124-Rcross-over |
| Sequence D | Experimental | Drug: DW5124, Drug: DW5124-Rcross-over |
| Sequence E | Experimental | Drug: DW5124, Drug: DW5124-Rcross-over |
| Sequence F | Experimental | Drug: DW5124, Drug: DW5124-Rcross-over |
Who may qualify
- Ages
- 19 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Healthy Volunteers who are ≥19 years and >65 years old
- Body weight ≥50.0 kg and BMI between 18.0 and 30.0 kg/m2
Key exclusion criteria (2 listed)
- Clinically significant Medical History
- In the case of women, pregnant(Urine-HCG positive) or lactating women
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| DW5124DW5124 on fasted or fed condition | Drug | Sequence A, Sequence B, Sequence C, Sequence D, Sequence E, Sequence F |
| DW5124-RDW5124-R on fasted or fed condition | Drug | Sequence A, Sequence B, Sequence C, Sequence D, Sequence E, Sequence F |
Primary outcome
Peak Plasma Concentration (Cmax)
Time frame: up to 72 hour
Pharmacokinetics of DW5124-fed and DW5124-fasting, Pharmacokinetics of DW5124-fed and DW5124-R-fed
Area under the plasma concentration versus time curve (AUC)
Time frame: up to 72 hour
Pharmacokinetics of DW5124-fed and DW5124-fasting, Pharmacokinetics of DW5124-fed and DW5124-R-fed
4 secondary outcomes
Time to maximum plasma concentration (Tmax)
Time frame: up to 72 hour
Terminal half life (t1/2)
Time frame: up to 72 hour
Apparent clearance (CL/F)
Time frame: up to 72 hour
Apparent volume of distribution (Vd/F)
Time frame: up to 72 hour
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Jan 2026.
Related trials for Mixed Dyslipidemia
Active, not recruitingObservational study
Study Evaluating LDL-C Change and Adherence to Inclisiran Lipid-lowering Therapy in ASCVD
Primary Hypercholesterolemia, Mixed Dyslipidemia
RecruitingObservational study
A Study of Bempedoic Acid or Its Single-pill Combination Therapy With Ezetimibe in Patients With Primary Hypercholesterolaemia or Mixed Dyslipidaemia
Primary Hypercholesterolaemia, Mixed Dyslipidemia
RecruitingPhase 1/2
Study of ARO-DIMERPA in Adult Participants With Mixed Hyperlipidemia
Hyperlipidemia; Mixed
Active, not recruitingObservational study
Treatment With Bempedoic Acid and/or Its Fixed-dose Combination With Ezetimibe in Primary Hypercholesterolemia or Mixed Dyslipidemia
Hypercholesterolemia, Mixed Dyslipidemia
Active, not recruitingObservational study
A Study of Bempedoic Acid in Combination With Ezetimibe and Either Rosuvastatin or Atorvastatin in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia
Primary Hypercholesterolemiia, Mixed Dyslipidemia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing DW5124 and DW5124-R in people with Mixed Dyslipidemia, run by Daewon Pharmaceutical Co., Ltd. at 1 site in South Korea.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 6 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in South Korea. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Peak Plasma Concentration (Cmax) (time frame: up to 72 hour). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Jan 2026.